UTMB’s Fangjian Guo and colleagues presented their research showing that women who receive the HPV vaccine may be more likely to be infected with certain high-risk strains of the virus than women who do not get the vaccine at the meeting of the American Association for Cancer Research this week. The new findings suggest that women previously vaccinated against HPV may benefit from a new HPV vaccine, called Gardasil 9, which protects against the original four strains plus five more strains of HPV that cause about 20 percent of cervical cancers, the researchers said. Gardasil 9 was approved in December 2014 for women ages 9 to 26.